5-Star Stocks Poised to Pop: Meridian Bioscience

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, diagnostic test maker Meridian Bioscience (Nasdaq: VIVO  ) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Meridian Bioscience's business and see what CAPS investors are saying about the stock right now.

Meridian Bioscience facts

Headquarters (Founded) Cincinnati (1976)
Market Cap $756.1 million
Industry Health-care supplies
Trailing-12-Month Revenue $171.2 million
Management CEO John Kraeutler (since 2008)
CFO Melissa Lueke (since 2001)
Return on Equity (Average, Past 3 Years) 21.1%
Cash/Debt $27.9 million / $0
Competitors Abbott Labs
Becton, Dickinson
Siemens Healthcare Diagnostics

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97% of the 478 members who have rated Meridian Bioscience believe the stock will outperform the S&P 500 going forward.

Earlier last week, one of those bulls, TempoAllegro, succinctly summed up the bull case for our communty:

[Meridian Bioscience] makes a range of diagnostic tests for foodborne, parasitic, viral, and other diseases that you can do at home. ...

With increasing threats to the food supply and environmental concerns such as lack of proper water for both humans and livestock, these tests will be both helpful and in greater demand in coming years.

Add to that its great balance sheet -- currently with zero debt and current ratio of over 5, plus high insider ownership, generous dividend, and 5-year projected growth in the mid-teens, and we have an excellent addition to anyone's health-oriented portfolio.  

If you want market-thumping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its five-star rating, Meridian Bioscience may not be your top choice.

We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.  

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool owns shares of Abbott. Motley Fool newsletter services have recommended buying shares of Becton. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2018250, ~/Articles/ArticleHandler.aspx, 10/24/2014 3:51:00 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement